Pennytobuck Update On Heme, Stemcell (stem) And Regn
Healthmed Services, Ltd
Healthmed Services, Ltd. (OTC:HEME), is developing a remote software product that will mobilize healthcare professionals and increase their efficiency by allowing them to interact with their stationary PC and do electronic charting from anywhere in the facility and also also them to update patient records, all via an iPAd. The product is an innovative measure that will simplify record-keeping.
HEME, an innovative software development company, is pleased with the recent studies and reports on information technology spending. HEME foresees their products as being a nice fit in the technology upgrades being made as part of the healthcare industry modernization. It is expected that healthcare spending in general could reach 4.5 trillion dollars by 2019.
President Obama has pledged 630 billion dollars over the next 10 years to the industry.
The US American Recovery and Reinvestment Act of 2009 has already awarded 70 billion dollars through the US Department of Health and Human Services to the healthcare industry. According to Juniper Research, spending on mobile hardware, software and services across the global healthcare sector is set to rise to $2.7 billion in 2010.
According to Forresters research for the first quarter, U.S. spending on information and communications technology products and services will reach 741 billion dollars in 2010.
HEME is optimistic their objective is in concert with the plans and goals of the healthcare industry. HEME will continue to build products and services that help professionals work more efficiently, help organizations provide convenience to their staff, and add value to the technical side of healthcare.
HealthMed also plans to provide online services through its Web site that includes a public portal, a Web site for individuals, consumers, and the general public that is designed to provide health information and recommendations; and a private and custom-designed/client-specific portal, a private-labeled Web site that would allow employees to access their personal health records and research various health and medical related topics, as well as provide access to information and resources to assist them in making personal health plan and medical treatment decisions.
You may read more about HEME and its product developments on its website: www.healthmedltd.com
Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast its presentation at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010.The presentation is scheduled for 1:00 p.m. Eastern Time.
The session may be accessed through REGN's web site, www.regeneron.com, on the Investor Relations page.An archived version of the presentation will be available after the live webcast through October 13, 2010.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.In addition to ARCALYST (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.
Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.
StemCells, Inc. (Nasdaq:STEM) announced recently that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem (ES) cells. This breakthrough, published this month in the international peer-reviewed journal Nature, opens the door to the types of genetic manipulations previously only possible in mice, and paves the way for modeling a broader range of human diseases with the rat. Both mice and rats are used as animal models of human disease; however certain aspects of the rats physiology, behavior, and metabolism are closer to the human, making rats the preferred species for drug development and studying human disease. The creation of this first rat model using rat ES cells validates intellectual property owned by StemCells, which includes the rights to patents covering both rat ES and rat induced pluripotent stem (iPS) cells as well as genetically engineered rats derived from these cells.
STEM's broad rat pluripotent stem cell intellectual property portfolio is based upon groundbreaking research led by prominent academic researchers at the University of Edinburgh, including Dr. Qi-Long Ying who was the first to succeed in deriving and culturing the true germline competent rat ES cells required for precise genetic engineering. In this newly published study, Dr. Qi-Long Ying and his colleagues at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California demonstrated for the first time the creation of genetically modified rats using rat ES cells that have been gene targeted via homologous recombination, a method which involves adding DNA sequences to the cells to delete ('knock-out'), add ('knock-in') or otherwise modify genes of interest. This latest work resulted in the successful generation of knock-out rats missing the tumor suppressor gene p53 for use in studying cancer1, and serves as a proof-of-principle for creating genetically engineered rats using rat ES cells.
StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and liver. StemCells lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the SC Proven(R)brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. The Company has exclusive rights to approximately 55 issued or allowed U.S. patents and over 200 granted or allowed non-U.S. patents.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars in cash from a third party (Media Elite Consultants LLC) for (1) day of advertising for Healthmed Services Ltd. (OTC BB: HEME.OB)
by:Bill Pennyman
Hisense: How To Buy Home Appliances To The Countryside Of The Flat Big Three Meet The Domestic Home Appliance Giant, Will Stage A Battle In Xiamen Industry Market Boom Set Off Lots Of Small Home Appliances Market Trap The Whole Kitchen Is Called "pot Of Gold At The Last Home Appliance Industry" Xinhua All 200 Million Into The Home Appliance Industry In March Also 将有大动作 Ceos Talk About The Digital Consumer Appliances Communicate Love In Home Appliances Home Appliance Trading Day Briefing (12/03/2009) "recall System" In The Field Of Home Appliances To Work? How to Avoid Cell Phone Radiation Separation Technology Centrifuges For Medical Laboratories Latest In the Electronic World The Differences Between Radiations Laboratory Experiments And High Concentrations Of Asbestos Fibers